Toxicity trips Vertex's timing

Long-term animal toxicity studies are routinely continued when a compound is already in the clinic. One of the downsides is that new findings can set back clinical progress significantly, which was illustrated last week when Vertex Pharmaceuticals Inc. decided to halt development of its VX-745 p38 MAP kinase

Read the full 485 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers